Long‐term data from a phase 3 study of radotinib versus imatinib in patients with newly diagnosed, chronic myeloid leukaemia in the chronic phase (RERISE)

In the phase 3 study RERISE, patients with newly diagnosed chronic myeloid leukaemia in chronic phase demonstrated significantly faster and higher rates of major molecular response (MMR) with twice‐daily radotinib 300 mg (n = 79) or 400 mg (n = 81) than with once‐daily imatinib 400 mg (n = 81) after...

Descripción completa

Detalles Bibliográficos
Autores principales: Do, Young Rok, Kwak, Jae‐Yong, Kim, Jeong A., Kim, Hyeoung Joon, Chung, Joo Seop, Shin, Ho‐Jin, Kim, Sung‐Hyun, Bunworasate, Udomsak, Choi, Chul Won, Zang, Dae Young, Oh, Suk Joong, Jootar, Saengsuree, Reksodiputro, Ary Harryanto, Lee, Won Sik, Mun, Yeung‐Chul, Kong, Jee Hyun, Caguioa, Priscilla B., Kim, Hawk, Park, Jinny, Kim, Dong‐Wook
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Haematological Malignancy‐Clinical
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7187446/
https://www.ncbi.nlm.nih.gov/pubmed/32012231
http://dx.doi.org/10.1111/bjh.16381

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7187446/
https://www.ncbi.nlm.nih.gov/pubmed/32012231
http://dx.doi.org/10.1111/bjh.16381

Ejemplares similares